Amid increasing concern about how new federal policies could undermine drug development, a new white paper from the USC Schaeffer Center for Health Policy & Economics examines how tax policies could support America’s leadership in biomedical innovation.

The researchers found that lowering corporate income tax rates may be more effective in encouraging innovation than commonly used tax strategies.

Darius Lakdawalla, PhD, chief scientific officer at the Schaeffer Center and professor at the USC Mann School of Pharmacy and Pharmaceutical Sciences and the USC Price School of Public Policy, served as the lead author.

To read more, click here.